Navigation Links
Genesis Biopharma Issues Letter To Shareholders
Date:5/21/2012

LOS ANGELES, May 21, 2012 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer immunotherapies, announces the posting of the following Letter to Shareholders to the Investors section of the Company's website at www.genesis-biopharma.com.  In addition, on May 15, 2012, the Company filed with the U.S. Securities and Exchange Commission its Quarterly Report for the three months ended March 31, 2012 on Form 10-Q.  The Form 10-Q includes unaudited interim consolidated financial statements containing the information highlighted below, as well as additional information regarding the Company.  The Form 10-Q is available at www.sec.gov or www.genesis-biopharma.com

Dear Shareholders:

The past months have been a productive and exciting time for Genesis Biopharma as we worked diligently to advance the clinical development of our targeted cancer immunotherapy, a ready-to-infuse autologous cell therapy ("ACT") utilizing tumor infiltrating lymphocytes ("TILs") for the treatment of patients with Stage IV metastatic melanoma.  ACT is based on a physician-sponsored investigational therapy currently available at the National Cancer Institute ("NCI"), MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute for this same indication. 

During the fourth quarter of 2011, we were pleased to announce our Patent License Agreement with the National Institutes of Health ("NIH"), under which Genesis Biopharma was granted a non-exclusive worldwide license to 43 patents and patent applications.  These include nine U.S. issued patents, 13 U.S. patent applications, and 21 foreign corresponding patents and patent applications relating to adoptive cell therapy using autologous TILs for the treatment of certain cancers. 

W
'/>"/>

SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants
2. ValGenesis Suite 2.5 Certified by SAP as Powered by SAP NetWeaver®
3. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
4. ThermoGenesis Announces Approval of AXP® by India Ministry of Health
5. ThermoGenesis Announces Acceptance of AXP® Submission by Regulatory Body in China
6. Genesis Biosciences Announces New Hire and Promotions on Operational and Scientific Staff
7. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2011 on September 12, 2011
8. Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies
9. Genesis Biopharma Names Former Member of the Joint Chiefs of Staff General Merrill McPeak to Board of Directors
10. Genesis Biopharma Names David Voyticky to Board of Directors
11. Genesis Biopharma Director William H. Andrews, Ph.D., Profiled in Popular Science Feature Story
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Theravalues Corporation est fier d,annoncer le ... au salon Hi Europe 2014 (du 2 au ... Curcumine la plus biodisponible actuellement sur le ... des ingrédients approuvés par les règlements européens. ... dans la racine de curcuma ( Curcuma longa ...
(Date:11/26/2014)... , 25 novembre 2014 /PRNewswrie/ -- Theravalues Corporation ... il mercato europeo in occasione di Hi Europe 2014 ... ). Si tratta della curcumina con la ... amorfa (senza cristalli) e ingredienti approvati dalle norme europee. ... nella spezia della pianta curcumina ( Curcuma longa ) ...
(Date:11/24/2014)... 24, 2014  IGI Laboratories, Inc. (NYSE MKT: IG), ... generic pharmaceutical company, today announced it has submitted an ... Food and Drug Administration (FDA), which brings the Company,s ... with eighteen submissions now pending at the FDA. ... of the Company, commented, "Our team here at IGI ...
(Date:11/24/2014)... Nov. 24, 2014  Last week, Representatives ... (D-NC) took a bold bipartisan step on ... the OPEN Act. Original co-sponsors of the legislation ... Act will incentivize drug makers and innovators to ... and pediatric cancers, which opens the door to ...
Breaking Biology Technology:La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3IGI Laboratories, Inc. Announces ANDA Submission 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
... Duke University bioengineers have not only figured out a ... cells, they can now slip them into the command center ... report back important information or drop off payloads. Using ... that has an uncanny ability to penetrate human cells, ...
... 28 /PRNewswire-FirstCall/ - Neuro-Biotech Corporation (PINKSHEETS: MRES) (OTCQB: MRES) ... 1 SymPath(R) TO EVALUATE THE ... (DBH), THAT IS RELEASED WITH NORADRENALINE WITHIN THE BLOOD ... NEURO # 2 AXIS(TM) ...
... Sept. 28 /PRNewswire-Asia-FirstCall/ -- ... ... ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
Cached Biology Technology:Sneaking spies into a cell's nucleus 2Sneaking spies into a cell's nucleus 3NEURO-BIOTECH DISCLOSES ITS LIST OF LICENSES 2Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 2Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 3Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 4Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 5Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 6Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 7Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 8
(Date:11/7/2014)... -- Leading Biometric companies aim to provide consumers ... transactions.  Companies in focus today are: NXT-ID, Inc. (NASDAQ: ... ), Google Inc. (NASDAQ: GOOG ), Microsoft Corporation ... EBAY ) and MasterCard Inc. (NYSE: MA) NXT-ID, ... authentication company focused on the growing mobile commerce is pleased ...
(Date:11/6/2014)... cancer deaths occur because of metastasis, yet progress ... been slow. , "It,s been particularly challenging to ... Gujral, research fellow in systems biology at Harvard ... detected until after they,ve already metastasized." , Gujral ... that should help researchers better understand how metastasis ...
(Date:11/6/2014)... Medicine, Inc, a Baltimore-based bioinformatics company focused on ... a research collaboration with the international leader in ... CSBR). , "There are many companies utilizing advances ... TumorGraft technology is unique in a way that ... vast amounts of valuable data. Our bioinformatic analysis ...
Breaking Biology News(10 mins):Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6Migration negation 2Migration negation 3Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... with backache caused by nerve root pain ?commonly known ... if therapeutic ultrasound can help their condition. , Dr ... for Rehabilitation Science need 30 volunteers aged 22-55 who ... not pregnant and have not had previous spinal surgery. ...
... in high tech tools, researchers have identified three proteins ... to 20 months before the rejection occurred. , Lung ... recipients, about 45% over five years, said lead investigator ... way to predict which transplants will fail, and when ...
... the survival of many types of cells stimulates rapid ... connect the cerebral cortex with the spinal cord and ... sclerosis (ALS or Lou Gehrig's disease). In the ... Massachusetts General Hospital (MGH) and the Harvard Stem Cell ...
Cached Biology News:Proteins may predict lung transplant rejection 2Proteins may predict lung transplant rejection 3Growth factor stimulates rapid extension of key motor neurons in brain 2